Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040)

Gợi ý tài liệu liên quan:

• Differences between physician and patient preferences for cancer treatments: A systematic review

  13 trang 167 0 0

• Prognostic impact of the number of metastatic lymph nodes after surgery in locally advanced hypopharyngeal cancer

  6 trang 166 0 0

• Immune checkpoint inhibitors and their impact on liver enzymes and attenuation

  7 trang 139 0 0

• 2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France

  9 trang 109 0 0

• Development and validation of the chemotherapy-induced peripheral neuropathy integrated assessment – oxaliplatin subscale: A prospective cohort study

  12 trang 87 0 0

• LAP3 contributes to IFN-γ-induced arginine depletion and malignant transformation of bovine mammary epithelial cells

  19 trang 72 0 0

• Eribulin normalizes pancreatic cancer-associated fibroblasts by simulating selected features of TGFβ inhibition

  17 trang 60 0 0

• Determinants of late-stage cervical cancer presentation in Ethiopia: A systematic review and meta-analysis

  9 trang 35 0 0

• The role of spleen volume change in predicting immunotherapy response in metastatic renal cell carcinoma

  11 trang 35 0 0

• Anti-proliferative activity of RIHMSQi-23 against MCF-7 breast cancer cell line is through inhibition of cell proliferation and senescence but not inhibition of targeted kinases

  12 trang 33 0 0